|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
'High-expression' variants of TS 2R/3R repeat, TS enhancer region 3R G/C, TS 1494del6 bp, and TS haplotype analysis might help to identify stage II and stage III colon cancer patients who are at great risk of developing tumor recurrence, and also those who are more likely to benefit from 5-fluorouracil-based adjuvant chemotherapy.
|
18192902 |
2008 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
|
12763222 |
2003 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
|
15355913 |
2004 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
|
15749593 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
|
16609021 |
2006 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
|
16609021 |
2006 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
|
17290389 |
2007 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil.
|
27685916 |
2017 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
|
7763285 |
1995 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
|
20966539 |
2010 |
|
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
|
21630057 |
2011 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arsenic trioxide (ATO) has been shown to suppress TYMS in a colonic cancer model.
|
24691991 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cell death due to thymine (dThd) deficiency, associated with the cytotoxic action of 5-fluorouracil in colon cancer, is regulated in thymidylate synthase-deficient (TS(-)) human colon carcinoma cells via the Fas (CD95, APO-1) death receptor.
|
10744679 |
2000 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of thymidylate synthase is associated with a higher risk of lymph node metastasis in patients with T3 colon cancers.
|
16332476 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EMAST was more frequent in colon cancer than rectal cancer (p=0.033), and associated with MSI-H phenotype (p<0.001), low expression of hMSH3 (p=0.004), and overexpression of thymidylate synthase (p=0.006).
|
27889996 |
2016 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
|
10537302 |
1999 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
For these studies, we used a TS-depleted human colon cancer HCT-C cell that had been transfected with either the human TS cDNA or the Escherichia coli TS gene.
|
10097112 |
1999 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the reduction of TS expression resulted in enhancement of the sensitivity to 5-FU in human colon cancer DLD-1 cells.
|
18425338 |
2008 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.
|
17016601 |
2006 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genotypes resulting in reduced MTHFR activity in conjunction with low TS expression were associated with a reduced risk of colon cancer.
|
16284371 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genotypes resulting in reduced MTHFR activity in conjunction with low TS expression were associated with a reduced risk of colon cancer.
|
16284371 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that the enhanced HSP90 function and subsequent activation of Src induce expression of TYMS and acquired resistance to 5-FU in colon cancer.
|
26416450 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
High TS was only found in 9.3% of rectal tumors, but in 29.7% of colon cancers (p=0.0042).
|
23968134 |
2013 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the relationship between the expressions of TS and E2F1 in primary colon cancer specimens remains unclear.
|
10914714 |
2000 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer).
|
18652704 |
2008 |